Cargando…

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), has significantly improved the survival of non-small cell lung cancer (NSCLC) patients with EGFR(T790M) mutation, the major mechanism of acquired resistance to first-generation EGFR TK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Mengzhen, Zhang, Tao, Chen, Hao, Song, Peiran, Tong, Linjiang, Chen, Jiaying, Liu, Yingqiang, Ning, Yi, Feng, Fang, Li, Yan, Tang, Haotian, Chen, Yi, Fang, Yan, Lu, Xiaoyun, Geng, Meiyu, Ding, Ke, Yu, Ker, Ding, Jian, Xie, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809337/ https://www.ncbi.nlm.nih.gov/pubmed/36605493 http://dx.doi.org/10.7150/jca.77788

Ejemplares similares

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
por: Liu, Yingqiang, et al.
Publicado: (2021)

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK
por: Song, Peiran, et al.
Publicado: (2022)

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2020)

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2021)

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
por: Zhang, Tao, et al.
Publicado: (2023)

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
por: Liu, Yingqiang, et al.
Publicado: (2023)

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
por: Huang, Kuo-Yen, et al.
Publicado: (2021)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Spectra library assisted de novo peptide sequencing for HCD and ETD spectra pairs
por: Yan, Yan, et al.
Publicado: (2016)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

Gamma heavy chain disease (γ-HCD) as iatrogenic immunodeficiency- associated lymphoproliferative disorder: Possible emergent subtype of rheumatoid arthritis-associated γ-HCD
por: Tsunemine, Hiroko, et al.
Publicado: (2019)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
por: Zhou, Yuanfeng, et al.
Publicado: (2012)

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2018)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
por: Fang, Yue, et al.
Publicado: (2023)

RDD-HCD Provides Variable Fragmentation Routes Dictated by Radical Stability
por: Silzel, Jacob W., et al.
Publicado: (2023)

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data
por: James, Gareth D., et al.
Publicado: (2016)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2019)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
por: Osoegawa, Atsushi, et al.
Publicado: (2021)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

pGlyco: a pipeline for the identification of intact N-glycopeptides by using HCD- and CID-MS/MS and MS3
por: Zeng, Wen-Feng, et al.
Publicado: (2016)

Identification of Potent EGFR Inhibitors from TCM Database@Taiwan
por: Yang, Shun-Chieh, et al.
Publicado: (2011)

Edition Eulenburg No. 797, Horn Concerto, : Mi♭ majeur - E♭ major - Es dur KV 495 /

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
por: Zhou, Rengui, et al.
Publicado: (2021)

797. Tuberculosis Treatment: Combined Forms vs. Dissociated Forms
por: Trigui, Maroua, et al.
Publicado: (2018)

Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
por: Chen, Jianxin, et al.
Publicado: (2020)

Improved Precision of iTRAQ and TMT Quantification by an Axial Extraction Field in an Orbitrap HCD Cell
por: Pichler, Peter, et al.
Publicado: (2011)

Comprehensive Plasma N-Glycoproteome Profiling Based on EThcD-sceHCD-MS/MS
por: Mao, Yonghong, et al.
Publicado: (2022)

Stevens–Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
por: Chen, Yang, et al.
Publicado: (2023)

Humanized CD36 (hCD36) mouse model supports the preclinical evaluation of therapeutic candidates targeting CD36
por: Xie, Xiulong, et al.
Publicado: (2023)

Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents
por: Arafet, Kemel, et al.
Publicado: (2023)

Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
por: Shi, Jingjing, et al.
Publicado: (2023)

The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo
por: Ma, Jingui, et al.
Publicado: (2008)

Increases in Entamoeba histolytica Antibody–Positive Rates in Human Immunodeficiency Virus–Infected and Noninfected Patients in Japan: A 10-Year Hospital-Based Study of 3,514 Patients
por: Yanagawa, Yasuaki, et al.
Publicado: (2016)

797 Viral co-infections in hospitalized patients with respiratory tract infections
por: Al-Nakib, Widad, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1akvipfvsg5manf802ssuokh7r